Aprotinin mediated antioxidant effect in Cardiosurgery with mechanical cardiorespiratory support (CMCS).
BACKGROUND
Aprotinin has been used in cardiosurgery as a hemostatic agent. Considering the implication of oxygen reactive species and proteases in the pathogenesis of Systemic Inflammatory Response Syndrome, we hypothesized that aprotinin may exert an antioxidant effect. This work was designed to evaluate the antioxidant capacity of aprotinin in vitro and in vivo in child patients undergoing cardiosurgery with mechanical cardiorespiratory support.


METHODS
Colorimetric techniques and chemiluminiscent emission assays. A blind controlled clinical trial was performed with a control (G-1, n=14, without aprotinin) and treated with aprotinin (G-2, n=12) groups (both assessed by medical decision) of child patients undergoing cardiosurgery with mechanical cardiorespiratory support. Blood samples were taken at: T-0 (induction of anesthesia), T-1 (10 minutes after begining of perfusion), T-2 (5 minutes after anoxic heart arrest), T-3 (ending operation) and T-4 (24 hours after operation).


RESULTS
We proved that aprotinin has no hydroxyl radical, superoxide anion nor H2O2 scavenger capacity as well as its capacity for inhibiting in vitro activated-leukocyte chemiluminiscence. Malonildialdehyde levels were higher in G-1 than G-2 with the greatest difference at T-2 (7.2+/-3.6 nmol/ml in G-1 vs 4+/-1.65 in G-2). Phospholipase A2 activity showed a tendency of higher values in G-1 than G-2 although there was no statistical significance. Uric acid concentration was greater in G-2 at T-1, T-2, T-3 and T-4 than G-1 and catalase activity was higher in G-2 at T-0, T-2 and T-3 than G-1 with noteworthy difference only at 5 minutes after anoxic heart arrest. Low cardiac output, arrhythmias and sudden death in the early postoperative phase were less frequent in the treated group.


CONCLUSIONS
These results suggest that aprotinin exerts a primary antioxidant activity and its protective effects in cardiosurgery seem to be associated with reduction of systemic oxidative stress.
Division of Oxidative Stress, Biomedical Research, Centre Victoria de Girón, Havana, Cuba. felixcu@latinmail.com
F
F
Broche
A
A
Romero
E
E
Olembe
E
E
Céspedes
M
M
Peña
C
C
Romay
J C
JC
García
D000975:Antioxidants / Q000627:therapeutic use*; D007611:Aprotinin / Q000627:therapeutic use*; D006348:Cardiac Surgical Procedures; D002374:Catalase / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003124:Colorimetry; D005112:Extracorporeal Circulation; D006801:Humans; D066298:In Vitro Techniques; D008163:Luminescent Measurements; D018384:Oxidative Stress / Q000187:drug effects; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D012121:Respiration, Artificial; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism
D000975:Antioxidants; D017392:Thiobarbituric Acid Reactive Substances; D014527:Uric Acid; D007611:Aprotinin; D002374:Catalase; D010741:Phospholipases A; D054467:Phospholipases A2